Evidence map›Paper›PMID 29477660›Full record

ReviewGynecologic oncology2018

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Stephanie Lheureux, Carolyn McCourt, B J Rimel, Linda Duska, Gini Fleming, Helen Mackay, David Mutch, Sarah M Temkin, Jean Lynn, Elise C Kohn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephanie LheureuxPrincess Margaret Cancer Centre, Toronto, Canada.
Carolyn McCourtWashington University St. Louis, MO, United States.
B J RimelCedars Sinai Cancer Center, Los Angeles, CA, United States.
Linda DuskaUniversity of Virginia, Charlottesville, VA, United States.
Gini FlemingUniversity of Chicago, Chicago, IL, United States.
Helen MackayUniversity of Toronto, Sunnybrook, Toronto, Canada.
David MutchWashington University St. Louis, MO, United States.
Sarah M TemkinVirginia Commonwealth University, Richmond, VA, United States.
Jean LynnCoordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD, United States.
Elise C KohnCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States. Electronic address: kohne@mail.nih.gov.

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

The incidence of endometrial cancer (EC) in the U.S. has been rising, from an estimated annual incidence of 49,560 in 2013 to 61,380 in 2017. Meanwhile, the SEER-based relative survival of women with EC in the U.S. has remained flat [82.3% from 1987 to 1989, 82.8% from 2007 to 2013] and our recent increased understanding of EC biology and subtypes has not been translated into therapeutic advances. The U.S. National Cancer Institute (NCI) therefore convened a Uterine Clinical Trials Planning Meeting in January 2016 to initiate and accelerate design of molecularly-targeted EC trials. Prior to the meeting a group of experts in this field summarized available data, emphasizing data on human samples, to identify potentially actionable alterations in EC, and the results of their work has been separately published. The Clinical Trials Meeting planners focused on discussion of (1) novel trial designs, including window-of opportunity trials and appropriate control groups for randomized trials, (2) targets specific to serous carcinoma and promises and pitfalls of separate trials for women with tumors of this histology (3) specific recommendations for future randomized trials.

Indexed as

Clinical trialEndometrial cancerMolecular targetSerous

Identifiers

PMID29477660
PMCPMC9465931

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.